

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Application Number	NOT YET ASSIGNED
Filing Date	ON EVEN DATE HEREWITH
First Named Inventor	BORRELLI et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BORRELLI=2A

[illegible][illegible]

Examiner
Signature

Date
Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 4

Complete if Known

Application Number	NOT YET ASSIGNED
Filing Date	ON EVEN DATE HEREWITH
First Named Inventor	BORRELLI et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	BORRELLI=2A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AC	Arici A, Oral E, Bukulmez O, Duleba A, Olive DL, Jones EE: The effect of endometriosis on implantation: results from the Yale University in vitro fertilization and embryo transfer program. Fertil.Steril. 1996; 65:603-607	
	AD	Arici A, Tazuke SI, Attar E, Kliman HJ, Olive DL: Interleukin-8 concentration in peritoneal fluid of patients with endometriosis and modulation of interleukin-8 expression in human mesothelial cells. Mol.Hum.Reprod. 1996; 2: 40-45	
	AE	Arici A, Oral E, Attar E, Tazuke SI, Olive DL: Monocyte chemotactic protein-1 concentration in peritoneal fluid of women with endometriosis and its modulation of expression in mesothelial cells. Fertil.Steril. 1997; 67: 1065-1072	
	AF	Barbieri RL: New therapy for endometriosis. N.Engl.J.Med. 1988; 318: 512-514	
	AG	Baxter, A. D. and Montana, J. G. PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY. Chiroscience LTD. (WO9806696)	
	AH	Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N.Engl.J.Med. 1996; 334: 1717-1725	
	AI	Cheung AN: Oncogenes and other growth factors in gynaecological neoplasms. Curr.Opin.Obstet.Gynecol. 1996; 8: 46-51	
	AJ	Daddona, P. E., Ghayeb, J., Knight, D. M., Le, J., Siegel, S. A., and Vilcek, J. Monoclonal and chimeric antibodies to human TNF - useful for treating sepsis syndrome, cachexia, microbial infections, rheumatoid arthritis, inflammation, etc. Univ New York Medical Cent and Centocor, Inc. (WO9216553)	
	AK	Dawood MY: Considerations in selecting appropriate medical therapy for endometriosis. Int.J.Gynaecol.Obstet. 1993; 40 Suppl:S29-42: S29-S42	
	AL	Eisermann J, Gast MJ, Pineda J, Odem RR, Collins JL: Tumor necrosis factor in peritoneal fluid of women undergoing laparoscopic surgery. Fertil.Steril. 1988; 50: 573-579	
	AM	Eisermann J, Register KB, Strickler RC, Collins JL: The effect of tumor necrosis factor on human sperm motility in vitro. J.Androl. 1989; 10: 270-274	
	AN	Fiers W: Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991; 285: 199-212	
	AO	Gray PW, Aggarwal BB, Benton CV, et al: Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature 1984; 312: 721-724	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	NOT YET ASSIGNED
		Filing Date	ON EVEN DATE HEREWITH
		First Named Inventor	BORRELLI et al.
		Group Art Unit	
		Examiner Name	
Sheet 3	of 4	Attorney Docket Number	BORRELLI=2A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AP	Hahn DW, Carraher RP, Foldes RG, McGuire JL: Experimental evidence for failure to implant as a mechanism of infertility associated with endometriosis. Am.J.Obstet.Gynecol. 1986; 155: 1109-1113	
	AQ	Halme J: Role of peritoneal inflammation in endometriosis-associated infertility. Ann.N.Y.Acad.Sci. 1991; 622:266-74: 266-274	
	AR	Harada T, Yoshioka H, Yoshida S, et al: Increased interleukin-6 levels in peritoneal fluid of infertile patients with active endometriosis. Am.J.Obstet.Gynecol. 1997; 176: 593-597	
	AS	Ho HN, Wu MY, Yang YS: Peritoneal cellular immunity and endometriosis. Am.J.Reprod.Immunol. 1997; 38: 400-412	
	AT	Hornung D, Ryan IP, Chao VA, Vigne JL, Schriock ED, Taylor RN: Immunolocalization and regulation of the chemokine RANTES in human endometrial and endometriosis tissues and cells. J.Clin.Endocrinol.Metab. 1997; 82: 1621-1628	
	AU	Hunt JS, Chen HL, Hu XL, Tabibzadeh S: Tumor necrosis factor-alpha messenger ribonucleic acid and protein in human endometrium. Biol.Reprod. 1992; 47: 141-147	
	AV	Jacobs, C. A. and Smith, C. A. Treating TNF mediated inflammatory diseases with TNF antagonist - esp. soluble form of TNF receptor, opt. as fusion protein with human immunoglobulin Fc region, esp. for treating arthritis. Immunex Corp. (WO9406476)	
	AW	Koninckx PR, Meuleman C, Demeyere S, Lesaffre E, Cornillie FJ: Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil.Steril. 1991; 55: 759-765	
	AX	Koninckx PR, Martin D: Treatment of deeply infiltrating endometriosis. Curr.Opin.Obstet.Gynecol. 1994; 6: 231-241	
	AY	MacSween RNM: Muir's Textbook of pathology. Whaley K., 1993; 1024-1025	
	AZ	Malinak LR, Buttram VCJ, Elias S, Simpson JL: Heritage aspects of endometriosis. II. Clinical characteristics of familial endometriosis. Am.J.Obstet.Gynecol. 1980; 137: 332-337	
	BA	Matalliotakis I, Neonaki M, Zolindaki A, Hassan E, Georgoulas V, Koumantakis E: Changes in immunologic variables (TNF-a, sCD8 and sCD4) during danazol treatment in patients with endometriosis. Int.J.Fertil.Womens.Med. 1997; 42: 211-214	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	NOT YET ASSIGNED
		Filing Date	ON EVEN DATE HERewith
		First Named Inventor	BORRELLI et al.
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	BORRELLI=2A
Sheet	4	of	4

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BB	Mori H, Nakagawa M, Itoh N, Wada K, Tamaya T: Danazol suppresses the production of interleukin-1 beta and tumor necrosis factor by human monocytes. Am.J.Reprod.Immunol. 1990; 24: 45-50	
	BC	Nophar Y, Kemper O, Brakebusch C, et al: Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 1990; 9: 3269-3278	
	BD	Overton C, Fernandez-Shaw S, Hicks B, Barlow D, Starkey P: Peritoneal fluid cytokines and the relationship with endometriosis and pain. Hum.Reprod. 1996; 11: 380-386	
	BE	Pennica D, Nedwin GE, Hayflick JS, et al: Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312: 724-729	
	BF	Rana N, Braun DP, House R, Gebel H, Rotman C, Dmowski WP: Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis. Fertil.Steril. 1996; 65: 925-930	
	BG	Revelli A, Modotti M, Ansaldi C, Massobrio M: Recurrent endometriosis: a review of biological and clinical aspects. Obstet.Gynecol.Surv. 1995; 50: 747-754	
	BH	Roby KF, Laham N, Hunt JS: Cellular localization and steroid hormone regulation of mRNA encoding tumour necrosis factor receptor I in mouse uterus. J.Reprod.Fertil. 1996; 106: 285-290	
	BI	Shalaby MR, Laegreid WW, Ammann AJ, Liggitt HD: Tumor necrosis factor-alpha-associated uterine endothelial injury in vivo. Influence of dietary fat. Lab.Invest. 1989; 61: 564-570	
	BJ	Shalaby MR, Sundan A, Loetscher H, Brockhaus M, Lesslauer W, Espevik T: Binding and regulation of cellular functions by monoclonal antibodies against human tumor necrosis factor receptors. J.Exp.Med. 1990; 172: 1517-1520	
	BK	Waller KG, Shaw RW: Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. Fertil.Steril. 1993; 59: 511-515	
	BL	Zhang RJ, Wild RA, Ojago JM: Effect of tumor necrosis factor-alpha on adhesion of human endometrial stromal cells to peritoneal mesothelial cells: an in vitro system. Fertil.Steril. 1993; 59: 1196-1201	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.